A conversation with biotech leader, Sujal Shah, former CEO of CymaBay Therapeutics about his company's story arc, leadership, resilience, and building a biotech company in the face of adversity.
Questions?: [email protected]
Follow us on X: https://x.com/DrugDealinPod
Connect with Shivu: https://linktr.ee/shivusharma
Check out Big Pharma Sharma: https://bigpharmasharma.substack.com/
Connect with Kenny: https://www.linkedin.com/in/kennylalwani/
Disclaimer: The views and opinions expressed in this podcast are for informational and educational purposes only. They are not intended as medical advice and should not be used as a substitute for professional medical judgment or guidance. Always consult a qualified healthcare provider with any questions you may have regarding a medical condition or treatment.
00:00 Introduction to Biotech Leadership
03:00 Sujal Shah's Journey in Biotech
05:46 Leadership Philosophy and Team Dynamics
09:13 Navigating Challenges at CymaBay
11:48 The Development of seladelpar
15:07 Strategic Decisions in Drug Development
17:58 Clinical Trials and Regulatory Interactions
20:50 The NASH Study and Its Implications
47:10 Navigating Drug Development Challenges
49:07 The Patient-Centric Approach in Drug Development
51:56 Facing Clinical Setbacks and Organizational Resilience
53:36 Unexpected Findings and Immediate Reactions
01:00:27 The Emotional Toll of Drug Development
01:05:08 Rebuilding Purpose and Finding Answers
01:19:52 Patient Advocacy and Support During Crisis
01:23:30 Uncovering the Truth: The Role of Independent Panels 01:33:59 Independent Review and Safety Assurance
01:36:50 Leadership Challenges and Stakeholder Management 01:40:12 Resilience in Adversity
01:43:51 Turning Point: Stock Recovery and Investor Relations 01:47:07 Skepticism and Ongoing Challenges
01:55:00 Data Presentation and Competitive Landscape
02:01:11 Building a Robust Evidence Package
02:04:53 Reflections on Leadership and Future Aspirations